Chinonyerem Okoro, Annerleim Walton Diaz, W Marston Linehan, Peter L Choyke and Adam R Metwalli
Renal Cell Carcinoma (RCC) represents a significant cause of cancer related deaths in the United States and worldwide. Current conventional imaging modalities including Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) reveal high resolution images of structural abnormalities; but these same modalities often fail to provide the adequate accuracy, specificity and sensitivity for diagnosing RCC from benign lesions. This has prompted ongoing investigation of molecular imaging modalities as a non-invasive alternative to biopsy. Initial use of glucose-based imaging agents has proven insufficient for common RCC histologies which have led to the development of targeted radiotracers to improve sensitivity of these scans. Current trials are ongoing to characterize the best use of these new targeted agents. In addition, novel radiotracer agents to evaluate renal perfusion, renal tubular function are being created and investigated.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 